Skip to content

Study · Non-randomized trial · n = 16 · 1995

4 results

A small dose of human parathyroid hormone(1-34) increased bone mass in the lumbar vertebrae in patients with senile osteoporosis.

Sone T, Fukunaga M, Ono S, Nishiyama T

Mineral and electrolyte metabolism1 Jan 1995Cited by 28 (Europe PMC)

PMID7565456 (opens in a new tab)PepBankPUB-07565456
Publisher pageAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In patients with senile osteoporosis, hPTH(1-34) increased lumbar BMD from baseline.

    In plain wordsIn patients with senile osteoporosis, hPTH increased lower spine bone density from baseline.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseLumbar BMD
    Study

    n = 16

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    6 micrograms per day · subcutaneous · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The lumbar BMD increased significantly at the end of the treatment without decrease in the cortical bone mass.
    1 context sentence
    Summary · context
    In this study, the effects of hPTH(1-34) administered at a dose of 6 micrograms (20 units) per day subcutaneously for 26 weeks were investigated in 16 patients with senile osteoporosis.
  2. 02HumanNon-randomized trialEfficacy outcome

    In patients with senile osteoporosis, cortical bone mass did not decrease during hPTH(1-34) treatment.

    In plain wordsIn patients with senile osteoporosis, cortical bone mass did not decrease during hPTH treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeCortical bone mass
    Study

    n = 16

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    6 micrograms per day · subcutaneous · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    The lumbar BMD increased significantly at the end of the treatment without decrease in the cortical bone mass.
    1 context sentence
    Summary · context
    In this study, the effects of hPTH(1-34) administered at a dose of 6 micrograms (20 units) per day subcutaneously for 26 weeks were investigated in 16 patients with senile osteoporosis.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with senile osteoporosis, bone formation markers increased during hPTH(1-34) treatment.

    In plain wordsIn patients with senile osteoporosis, bone formation markers increased during hPTH treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseBone formation markers
    Study

    n = 16

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    6 micrograms per day · subcutaneous · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Biochemical markers of bone formation were also elevated, while markers of bone resorption did not show striking changes during the treatment.
    1 context sentence
    Summary · context
    In this study, the effects of hPTH(1-34) administered at a dose of 6 micrograms (20 units) per day subcutaneously for 26 weeks were investigated in 16 patients with senile osteoporosis.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with senile osteoporosis, bone resorption markers showed no striking changes during hPTH(1-34) treatment.

    In plain wordsIn patients with senile osteoporosis, bone breakdown markers showed no striking changes during hPTH treatment.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    No significant changeBone resorption markers
    Study

    n = 16

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    6 micrograms per day · subcutaneous · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    Biochemical markers of bone formation were also elevated, while markers of bone resorption did not show striking changes during the treatment.
    1 context sentence
    Summary · context
    In this study, the effects of hPTH(1-34) administered at a dose of 6 micrograms (20 units) per day subcutaneously for 26 weeks were investigated in 16 patients with senile osteoporosis.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.